Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health.

Synthego is on a mission to revolutionize genome engineering technology, helping translate genomics into the clinic and ultimately making engineered biological therapies accessible to all patients.

Synthego was founded in 2012 by Michael Dabrowski, Paul Dabrowski and Alex Pesch. The company is headquartered in Menlo Park, California.


Synthego leverages machine learning, automation and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company's platforms vertically integrate proprietary hardware, software, bioinformatics, chemistries and molecular biology to advance both basic research and therapeutic development programs.


Synthego's platforms are designed to produce standardized CRISPR reagents and engineered cells to enable more rapid and precise discovery, validation and genetic pathway analysis that scientists use to conduct basic research, target identification and clinical trials.


Synthego brought together more than 12,000 CRISPR researchers at the largest annual global CRISPR conference, leveraged its Eclipse Platform to rapidly accelerate critical programs in COVID-19 research and neurodegenerative diseases.


Synthego is backed by Founders Fund, Menlo Ventures, Intel Capital, Wellington Management, Perceptive Advisors, RA Capital Management, 8VC, SoftBank Vision Fund 2, Declaration Partners, and others. The company raised $200M in Series E round on Feb 17, 2022. This brings Synthego's total funding to $459.7M to date.



  • Year founded: 2012
  • Funding Info: $459.7M over 6 Rounds (Latest Funding Type: Series E)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: NA
  • City/Town: Menlo Park
  • State: California
  • Country: United States
Related businesses